March 26, 2021 07:59 AM EDT

EMA: Ongoing study data of Celltrion’s mAb enough to allow its use in some Covid-19 patients

Zachary Brennan

Senior Editor

The European Medicines Agency added another monoclonal antibody to the continent’s Covid-19 therapeutics arsenal on Friday, concluding that Celltrion’s regdanvimab can be used as a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA: Ongoing study data of Celltrion’s mAb enough to allow its use in some Covid-19 patients

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

EMA: On­go­ing study da­ta of Cell­tri­on’s mAb enough to al­low its use in some Covid-19 pa­tients

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

EMA: Ongoing study data of Celltrion’s mAb enough to allow its use in some Covid-19 patients